Dasatinib Anhydrous

CAS 302962-49-8

General Information

Dasatinib anhydrous is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.


Dasatinib was approved by the FDA in 2006 under the trade name Sprycel, for use as a second-line drug for patients with Ph+ CML or Ph+ ALL. It was approved in 2010 for use in newly diagnosed adults in the chronic phase. In addition, it is undergoing Phase II or III clinical trials for a wide range of uses (in breast cancer, prostate cancer, leukemia and non-small lung cancer). Dasatinib is synthesized through a chemical process involving carbon-nitrogen bond formation as a major step.

About the API

Systematic name N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
Trade name(s) Sprycel
Molecular Formula C22H26ClN7O2S
Molecular Weight 488.00554
Physical properties white powder
Therapeutic category Antineoplastic & Immunomodul
Available formulations Oral Solid
Regulations EU DMF Flag EU DMF